XPhyto Announces Drug Formulation Strategy And 2021 Milestones
- Construction of commercial drug manufacturing facility in Germany
- Four clinical studies in neurological indications in 2021
- Development of oral biosensor and contract development & manufacturing
- Psychedelic transdermal and sublingual drug formulation development
Vancouver, Canada (January 28, 2021) – XPhyto Therapeutics Corp. (CSE:XPHY / OTC:XPHYF / FSE:4XT) (“XPhyto” or the “Company”) is pleased to announce its drug formulation and delivery business strategy and milestones for 2021. As a bioscience accelerator at the leading-edge of the life science industry, XPhyto targets growth through commercialization of its product pipeline and focused investment in impact driven innovation with the potential for meaningful value creation.
Further to XPhyto’s press release dated January 18, 2021, the Company’s core milestones for this year include the commercialization of infectious disease diagnostics, the clinical validation of transdermal and sublingual drug formulations and continued investment in psychedelic medicine.
Regarding XPhyto’s drug formulation business, the Company is pleased to set out the strategy and milestones for 2021 of its wholly owned German subsidiary, Vektor Pharma TF GmbH (“Vektor”). Vektor will position itself for commercial manufacturing, pipeline development and drug formulations for critical mental health conditions.
“2021 is expected to be a transformative year for Vektor. We will be building on significant momentum from 2020 as we advance our drug formulation, contract development, and psychedelic business,” said Prof. Dr. Thomas Beckert, managing director of Vektor Pharma TF GmbH. “The addition of scalable in-house manufacturing capability creates the potential for significant growth across virtually all of our development and commercialization programs.”
Vektor is a German narcotics manufacturer, developer, and researcher located in the district of Biberach, Baden-Württemberg, Germany. For over a decade, the company and its team have been leaders in the design, testing and manufacture of thin film drug formulations, particularly transdermal patches and sub-lingual (oral) strips for the delivery of active pharmaceutical ingredients (“API”) for the treatment of pain and neurological conditions.
Commercial Manufacturing Facility
In anticipation of Vektor’s drug product commercialization schedule, and due to significant interest in contract manufacturing, Vektor is planning to build a new commercial drug manufacturing facility in Germany in 2021. Vektor has secured a property in the district of Biberach, near its current laboratory, and is currently in the due diligence process to ensure suitability of the land for construction and use as a commercial drug manufacturing and laboratory site. The estimated maximum capacity of laboratory and manufacturing space that could be constructed on the property is 3,000 m2 (32,000 ft2). The Company is reviewing scalable construction options to synchronize manufacturing capacity and demand with the Company’s projected growth and timelines.
As a vertically integrated drug formulation research, development and commercial production company, Vektor is well positioned to maximize the value of its physical and intellectual assets by way of: 1) development, manufacture and distribution of XPhyto products; and 2) contract development and/or manufacture of products for third-parties. The addition of in-house, scalable commercial drug manufacturing capability is expected to add significant value and optionality to XPhyto’s drug formulation business.
XPhyto’s drug formulation business is focused on neurological indications with strong market demand and the potential for improved patient outcomes. In 2020, XPhyto reported significant advancements in four drug formulation development programs. In 2021, the Company is planning to complete one clinical pilot study in each quarter as follows:
Q1) Rotigotine – transdermal patch in Parkinson’s disease;
Q2) CBD – oral/sublingual strip in treatment resistant Epilepsy;
Q3) THC – oral/sublingual strip in anorexia/nausea; and
Q4) CBD:THC (1:1) – oral/sublingual strip in Multiple Sclerosis associated spasticity.
Each study is planned to be carried out over an approximately two-week period as an open label, randomized, crossover, two-period, two-sequence, single dose pilot study to assess the relative bioavailability of each product. Pending positive results, the Company plans to advance the products toward a final pivotal study and application for regulatory approval. The Company is currently in discussions with multiple potential commercial partners, licensors and distributors and will be reviewing monetization opportunities on a continued basis. In-house commercial manufacturing is expected to provide additional value to potential purchasers, partners and licensors, and ultimately to XPhyto.
Development of Oral Biosensors and Contract Development & Manufacturing XPhyto’s diagnostic portfolio includes several novel peptide-based oral screening tests, under licence from 3a-diagnostics GmbH, for the detection of infectious diseases including influenza A, and oral health indications, such as peri-implantitis. In 2020, XPhyto confirmed successful activation of its peptide-based biosensor program when delivered using Vektor’s sublingual drug delivery platform. In 2021, XPhyto plans to continue development and validation of its biosensor products and plans to bring at least one biosensor product to market in Europe by yearend. In- house commercial manufacturing capacity, as set out above, is expected to maximize profitability of the biosensor commercialization.
Since its inception, Vektor has worked for major and emerging drug companies to develop new and generic dosage formulations based on its sublingual and transdermal drug delivery platforms. Vektor has produced generic drug formulations of Fentanyl, Rivastigmine, and Clonidine, as well as novel formulations of drugs in Parkinson’s disease, restless leg syndrome, incontinence, local pain and abuse-resistant pain medications. Further, Vektor is currently engaged in the development of a sublingual drug formulation for a major European generic drug company.
Vektor provides its clients with a versatile and rapidly adjustable sublingual and transdermal dosage platform to create new delivery options for generic and novel APIs. With the addition of in-house commercial manufacturing capacity, Vektor is building a vertically integrated thin film company to significantly grow its contract development and manufacturing business. Psychedelic Transdermal and Sublingual Drug Formulations Psychedelic compounds are a promising new class of API with potential for the treatment of mental health conditions such as depression, anxiety, addiction, and trauma-related stress disorder. Psychedelics could provide a major improvement over currently available therapeutics for a global market with unmet medical need.
Vektor will begin planning and development work for the incorporation of various psychedelic compounds into its drug formulations. This is facilitated by Vektor’s drug delivery platforms in combination with, XPhyto’s agreements for the development of industrial scale biotechnology processes for the production of psilocybin in Germany, and for the research and development of a broad range of psychedelic compounds, including psilocybin, mescaline, LSD, MDMA, DMT, in Canada.
XPhyto believes that the development of standardized drug formulations with precise, predictable and efficient API delivery for clinical study and therapeutic use, is critical to advancing the field of psychedelic medicine.
The Company will provide further information and updates for each of the business initiatives set out above in due course.